Menu

Whitethorn For House

Politics For All Parties

Cancer Treatment Centers of America Provide Prostate Cancer Screenings Through October

PR Newswire recently published an article provided by the Cancer Treatment Centers of America entitled, “Football League Alumni Association, Cancer Treatment Centers of America and Labcorp Team Up to Offer Prostate Cancer Screenings in September”. The article details the latest efforts to raise awareness and increase screenings of prostate cancer. Prostate cancer is common among men, afflicting one out of seven men.

Starting in the beginning of September and going through the middle of October, the NFLA and the Cancer Treatment Centers of America are joining Labcorp in the fight to educate men about the prevalent cancer by offering 2,000 free PSA screenings.

The Prostate Specific Antigen screening will also be available at a discounted rate of $25 throughout the campaign. The article discusses those who are high risk, namely African American men and those who have a family history of the disease.

There is also a Prostate Pep Talk campaign, hosted by head coaches of the NFL like Bill Cowher, Herm Edwards, and Dick Vermeil. Edwards has personally known many friends and co-workers who have been diagnosed, some who have unfortunately lost the fight.

The campaign began with a press conference in New Jersey with Beasley Reece, Edwards, Mike Quick, and Jon Runyan. It will also include a variety of events at different Cancer Treatment Centers of America around the country including cities like: Atlanta, Phoenix, and Tulsa.

Cancer Treatment Centers of America, or CTCA, encourages personalized treatment through precision medicine. They have experts that specialize in treating cancer and multidisciplinary care teams to help patients with therapies to manage side effects and remain strong during treatment.

Cancer Treatment Center of America also provides the Targeted Agent and Profiling Utilization Registry that seeks to understand how drugs perform on a range of cancers. They seek to match the drugs to the different kinds of tumors with genomic mutations.

Leave a Reply